Differential immunotoxicity of histone deacetylase inhibitors on malignant and naïve hepatocytes

Experimental and Toxicologic Pathology

Volumn 63, Issue 5, 2011, Pages 511-517

  Weiller, Markus ^a   Weiland, Timo ^a   Dünstl, Georg ^a   Sack, Ulrike ^a   Künstle, Gerald ^a   Wendel, Albrecht ^a  

^a UNIVERSITY OF KONSTANZ   (Germany)

Author keywords

Adverse side effect; CD95L; CFLIP; Hepatocellular carcinoma; Primary hepatocytes; TNF; TRAIL; XIAP

Indexed keywords

ANTINEOPLASTIC AGENT; APICIDIN; DACINOSTAT; ENTINOSTAT; FAS LIGAND AGONIST; FLICE INHIBITORY PROTEIN; HISTONE DEACETYLASE INHIBITOR; M 344; META CARBOXYCINNAMIC ACID BIS HYDROXAMIDE; N HYDROXY 7 ( 4 DIMETHYLAMINOBENZOL)AMINOHEPTANAMIDE; TUMOR NECROSIS FACTOR ALPHA AGONIST; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND AGONIST; UNCLASSIFIED DRUG; VALPROIC ACID; VORINOSTAT; X LINKED INHIBITOR OF APOPTOSIS;

ANIMAL CELL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL STRAIN HEPG2; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG POTENCY; DRUG SENSITIVITY; EPIGENETICS; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOTOXICITY; IN VITRO STUDY; LIVER CELL; MOUSE; NONHUMAN; SENSITIZATION; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CASPASE 3; CASPASE 7; CASPASE 8; CELL CULTURE TECHNIQUES; CELL SURVIVAL; FAS LIGAND PROTEIN; HEP G2 CELLS; HEPATOCYTES; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; LIVER; MICE; MICE, INBRED C57BL; PERFUSION; TRANSFECTION; TUMOR NECROSIS FACTOR-ALPHA;

MURINAE;

EID: 79955980009     PISSN: 09402993     EISSN: 16181433     Source Type: Journal    
DOI: 10.1016/j.etp.2010.04.001     Document Type: Article

References (38)

1. Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer 2002, 2(6):420-430.
2. Ashkenazi A., Dixit V.M. Apoptosis control by death and decoy receptors. Curr Opin Cell Biol 1999, 11(2):255-260.
3. Beg A.A., Baltimore D. An essential role for NF-kappaB in preventing TNF-alpha-induced cell death. Science 1996, 274(5288):782-784.
4. Bergmeyer H.U., et al. Optimization of methods for aspartate aminotransferase and alanine aminotransferase. Clin Chem 1978, 2(1):58-73.
5. Bortner C.D., Cidlowski J.A. Cellular mechanisms for the repression of apoptosis. Annu Rev Pharmacol Toxicol 2002, 42:259-281.
6. Candido E.P., et al. Sodium butyrate inhibits histone deacetylation in cultured cells. Cell 1978, 14(1):105-113.
7. Chopin V.C., et al. Synergistic induction of apoptosis in breast cancer cells by cotreatment with butyrate and TNF-alpha, TRAIL, or anti-Fas agonist antibody involves enhancement of death receptors' signalling and requires P21(waf1). Exp Cell Res 2004, 298(2):560-573.
8. Chopin V.C., et al. Sodium butyrate induces P53-independent, Fas-mediated apoptosis in MCF-7 human breast cancer cells. Br J Pharmacol 2002, 135(1):79-86.
9. Chu J.L., et al. Massive upregulation of the Fas ligand in lpr and gld mice: implications for Fas regulation and the graft-versus-host disease-like wasting syndrome. J Exp Med 2002, 181(1):393-398.
10. Dai Y., et al. Blockade of histone deacetylase inhibitor-induced RelA/p65 acetylation and NF-κB activation potentiates apoptosis in leukemia cells through a process mediated by oxidative damage, XIAP downregulation, and c-Jun N-terminal kinase 1 activation. Mol Cell Biol 2005, 25(13):5429-5444.
11. Drummond D.C., et al. Clinical development of histone deacetylase inhibitors as anticancer agents. Annu Rev Pharmacol Toxicol 2005, 45:495-528.
12. Dzieran J., et al. Differential responsiveness of human hepatoma cells versus normal hepatocytes to TRAIL in combination with either histone deacetylase inhibitors or conventional cytostatics. Cancer Sci 2008, 99(8):1685-1692.
13. Facchetti F.S., et al. Modulation of pro- and anti-apoptotic factors in human melanoma cells exposed to histone deacetylase inhibitors. Apoptosis 2004, 9(5):573-582.
14. Faraco G.T., et al. Pharmacological inhibition of histone deacetylases by suberoylanilide hydroxamic acid specifically alters gene expression and reduces ischemic injury in the mouse brain. Mol Pharmacol 2006, 70(6):1876-1884.
15. Finnin M.S., et al. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 1999, 401(6749):188-193.
16. Galle P.R., et al. Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage. J Exp Med 1995, 182(5):1223-1230.
17. Goettlicher M., et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. Embo J 2001, 20(24):6969-6978.
18. Hernandez A., et al. Butyrate sensitises human colon cancer cells to TRAIL-mediated apoptosis. Surgery 2001, 130(2):265-272.
19. Irmler M., et al. Inhibition of death receptor signals by cellular FLIP. Nature 1997, 388(6638):190-195.
20. Johnstone R.W. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discovery 2001, 1(4):287-299.
21. Kataoka T., et al. FLIP prevents apoptosis induced by death receptors but not by perforin/granzyme B, chemotherapeutic drugs, and gamma irradiation. J Immunol 1998, 161(8):3936-3942.
22. Koren G.K., et al. The effects of impaired liver function on the elimination of antineoplastic agents. Ann Pharmacother 1992, 26(3):363-371.
23. Leist M., et al. Murine hepatocyte apoptosis induced in vitro and in vivo by TNF-alpha requires transcriptional arrest. J Immunol 1994, 153(4):1778-1788.
24. Luo K.X., et al. In situ investigation of Fas/FasL expression in chronic hepatitis B infection and related liver diseases. J Viral Hepat 1997, 4(5):303-307.
25. Melnick A., Licht J.D. Histone deacetylases as therapeutic targets in hematologic malignancies. Curr Opin Hematol 2002, 9(4):322-332.
26. Mitsiades C.S., et al. Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc Natl Acad Sci USA 2004, 101(2):540-545.
27. Nagata S. Apoptosis by death factor. Cell 1997, 88(3):355-365.
28. Peart M.J., et al. Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. Proc Natl Acad Sci USA 2005, 102(10):3697-3702.
29. Pathil A., et al. HDAC inhibitor treatment of hepatoma cells induces both TRAIL-independent apoptosis and restoration of sensitivity to TRAIL. Hepatology 2006, 43(3):425-434.
30. Peter M.E., Krammer P.H. The CD95(APO-1/Fas) DISC and beyond. Cell Death Differ 2003, 10(1):26-35.
31. Rasheed W.K., et al. Histone deacetylase inhibitors in cancer therapy. Expert Opin Invest Drugs 2007, 16(5):659-678.
32. Rosato R.R., Grant S. Histone deacetylase inhibitors in cancer therapy. Cancer Biol Ther 2003, 2(1):30-37.
33. Sailhamer E.A., et al. Acetylation: a novel method for modulation of the immune response following trauma/hemorrhage and inflammatory second hit in animals and humans. Surgery 2008, 144(2):204-216.
34. Seglen P.O. Preparation of rat liver cells. 3. Enzymatic requirements for tissue dispersion. Exp Cell Res 1973, 82(2):391-398.
35. Vannini A., et al. Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor. Proc Natl Acad Sci USA 2004, 101(42):15064-15069.
36. Wallach D. Apoptosis. Placing death under control. Nature 1997, 388(6638):125-126. 123.
37. Witzig T.E., et al. Induction of apoptosis in malignant B cells by phenylbutyrate or phenylacetate in combination with chemotherapeutic agents. Clin Cancer Res 2000, 6(2):681-692.
38. Yeh W.C., et al. Requirement for casper (c-FLIP) in regulation of death receptor-induced apoptosis and embryonic development. Immunity 2000, 12(6):633-642.